ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported operating and financial results for the three and nine months ended September 30, 2015.
“The last few months were marked by a number of significant milestones. Most notably, on October 5, we received FDA approval for Optune in newly diagnosed glioblastoma. This approval increases our target patient population in the US by almost 70% and enables our sales and marketing organization to lead with the strong and impactful message of improved overall survival,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Our commercial organization was ready for the approval and our sales team is now actively promoting Optune as a superior therapy for newly diagnosed glioblastoma as we work to transform the standard of care.”
Help employers find you! Check out all the jobs and post your resume.
“The last few months were marked by a number of significant milestones. Most notably, on October 5, we received FDA approval for Optune in newly diagnosed glioblastoma. This approval increases our target patient population in the US by almost 70% and enables our sales and marketing organization to lead with the strong and impactful message of improved overall survival,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Our commercial organization was ready for the approval and our sales team is now actively promoting Optune as a superior therapy for newly diagnosed glioblastoma as we work to transform the standard of care.”
Help employers find you! Check out all the jobs and post your resume.
